SRU Biosystems has announced the issuance of their 20th patent in the field of label-free optical biosensors and instrumentation. The patent, US 7,264,973, includes claims specifically covering the label-free detection of cells on the Company’s optical biosensor.
The patent adds to the expansive coverage that the Company has secured for its core technologies, including its instrumentation, microplate designs, and product applications.
“The issuance of the 20th patent, with an additional 7 patent applications that have been allowed, is part our ongoing strategy for the Company to protect its broad intellectual property in the field of optical biosensors,” said Richard Wagner, President and CEO of SRU Biosystems.
“As part of our portfolio management, we will continue to seek worldwide protection for our innovative inventions in this exciting area.”
The patent is related to the SRU BIND® technology, including instrumentation, such as the BIND® Reader, capable of 96- and 384-well microplate detection.
The SRU BIND® Reader can be integrated into automated systems and represents solutions for antibody and small molecule/fragment screening, and cell-based applications.